血清抗苗勒管激素浓度与卵泡密度在生育期及不同疾病中的变化及其对生育力保存的意义
这项回顾性观察研究纳入830例在单一中心冻存卵巢组织的患病女性,分析血清AMH浓度与卵泡密度随年龄和疾病的变化。结果显示年轻女性中AMH与卵泡密度不相关,部分疾病中AMH降低而卵泡密度未降低,提示AMH预测卵泡密度的价值有限。
要点
- 年轻女性(≤20岁)中AMH浓度与卵泡密度不相关。
- 部分疾病如霍奇金淋巴瘤和妇科癌症中AMH降低但卵泡密度未降低。
- 仅依据AMH计算移植卵巢组织量可能不准确,卵泡密度可能是更好参数。
核心结论
- 年轻女性中AMH浓度与卵泡密度不相关,且部分疾病中AMH降低而卵泡密度未降低,限制了AMH作为卵巢组织移植预测参数的价值。
研究设计与样本
- 回顾性观察研究,纳入830例(平均年龄28.2±6.81岁,范围4-43岁)恶性疾病(n=806)和良性疾病(n=24)患者,在单一中心作为国家生育力保存项目的一部分冻存组织。
- 排除接受过卵巢手术或已知卵巢储备降低倾向的女性。
- AMH浓度在性腺毒性治疗前分析;标准化活检取自卵巢皮质不同区域,组织消化和钙黄绿素染色后分析卵泡密度,表示为每3mm活检和每立方毫米组织的平均原始和初级卵泡数。
主要发现
- 平均AMH浓度为3.1±2.81 ng/ml,每3mm活检平均卵泡密度为137±173.9,每立方毫米组织为19.4±24.60。
- AMH浓度在儿童和青少年6-10岁(5.71 ng/ml)及成人21-25岁(3.33 ng/ml)最高;卵泡密度在15岁以下幼儿中最高,随年龄增加而下降。
- AMH与卵泡密度在≤20岁女性中不相关,在21-40岁女性中弱至中度相关(r=0.24-0.39)。
- 在乳腺癌、白血病、肉瘤、胃肠道癌和妇科癌症等诊断组中显示年龄校正后的AMH与卵泡密度相关性,但在霍奇金和非霍奇金淋巴瘤、脑癌、其他恶性肿瘤和其他良性疾病组中未显示。
- 霍奇金淋巴瘤和妇科癌症等诊断组中AMH浓度降低但卵泡密度未降低。
临床怎么用
- 在一些年轻癌症患者中,应谨慎使用AMH估计总卵巢储备和卵泡密度。
- 仅基于AMH计算移植卵巢组织量可能不准确,卵泡密度可能是更好的参数。
局限性
- 尽管活检取自不同部位,卵泡的异质性分布可能对分析的准确性有一定影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY QUESTION: How do anti-Müllerian hormone (AMH) serum concentrations and follicle densities (FDs) change with age and disease and what are the implications for fertility preservation? SUMMARY ANSWER: AMH concentrations and FD do not correlate in young women, and AMH but not FD is reduced in some diseases, limiting the value of AMH as a predictive parameter of ovarian tissue transplantation. WHAT IS KNOWN ALREADY: AMH is widely used as a parameter to estimate the ovarian reserve. However, the reliability of AMH to predict total number of follicles and the FD is questionable. Women with lymphoma and leukaemia have been shown to have reduced AMH concentrations, but it is unknown if the FD is also reduced. In fertility preservation it is essential to estimate the correct total number of follicles and the FD, as ovarian tissue should only be cryopreserved if ovarian reserve is high. Furthermore, the amount of tissue to be transplanted should be based on the estimation of the real FD. STUDY DESIGN, SIZE, DURATION: This retrospective observational study included 830 women (mean ± SD age, 28.2 ± 6.81 years; range, 4-43 years) with malignant (n = 806) and benign (n = 24) diseases who cryopreserved tissue in a single centre as part of a national fertility preservation programme. Females with ovarian surgery or known predispositions for a reduced ovarian reserve were excluded. AMH concentrations and FD were evaluated from March 2011 to September 2016. PARTICIPANTS/MATERIALS, SETTING, METHODS: AMH concentrations were analysed before gonadotoxic therapies. Standardized biopsies, obtained from different areas of ovarian cortex, were collected. FD was analysed after tissue digestion and calcein staining and was expressed as average number of primordial and primary follicles count per 3 mm biopsy and per cubic millimeter tissue. AMH concentrations and FD were analysed in relation to age and diagnosis group. Both parameters were age adjusted, and associations between the different diagnosis groups and AMH versus FD were assessed. MAIN RESULTS AND THE ROLE OF CHANCE: Mean ± SD AMH concentration was 3.1 ± 2.81 g/ml, mean FD per 3 mm biopsy was 137 ± 173.9 and 19.4 ± 24.60 per mm3. Maximum AMH concentrations were found in children and teenagers at the age of 6-10 years (5.71 ng/ml) and in adults at the age of 21-25 years (3.33 ng/ml). FD was highest in young children up to an age of 15 years and decreased with increasing age. AMH and FD were not correlated in women ≤20 years and weakly to moderately correlated in women 21-40 years (r = 0.24-0.39). Age-adjusted correlations between AMH and FD were demonstrated in several diagnosis groups such as breast cancer, leukaemia, sarcoma, gastrointestinal cancer and gynaecological cancer but not in the groups exhibiting Hodgkin's and non-Hodgkin's lymphoma, cerebral cancer, other types of malignancies and other types of benign diseases. Further statistical analysis supported the finding that, in some diagnosis groups such as Hodgkin's lymphoma and in gynaecological cancer, AMH concentrations but not FDs are reduced, questioning the prognostic accuracy of AMH for the FD in these diseases. LIMITATIONS, REASONS FOR CAUTION: Even though biopsies were taken from different sites, heterogenous distribution of follicles might have had some effect on the accuracy of the analysis. WIDER IMPLICATION OF THE FINDINGS: AMH should be used with care to estimate the total ovarian reserve and FD of cancer patients in young women in some diseases. Therefore, calculating the amount of ovarian tissue to be transplanted based solely on AMH might be inaccurate whereas FD might be a better parameter. STUDY FUNDING/COMPETING INTEREST(S): The study did not receive any exterior funding.
引用
- Liebenthron J, Reinsberg J, van der Ven K, et al. Serum anti-Müllerian hormone concentration and follicle density throughout reproductive life and in different diseases-implications in fertility preservation. Hum Reprod. 2019. PMID: 31782794. doi:10.1093/humrep/dez215
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。